Out of the Lab, into the Patient: Canada’s Commercial Opportunity in Cell and Gene Therapy Manufacturing

Out of the Lab, into the Patient: Canada’s Commercial Opportunity in Cell and Gene Therapy Manufacturing

Innovation and Technology
Pages:17 pages22 min read

Author: The Conference Board of Canada

$0.00

Canada has a chance to be a leader in cell and gene therapy manufacturing. This research looks at state of this sector in Canada, highlighting both its strengths and the key gaps.

Want a discount? Become a member!

Originally produced for the Innovation Economy Council (IEC), this research examines the state of the Canadian cell and gene therapy sector and what needs to be done to help it grow. The IEC is now The Conference Board of Canada’s Canadian Centre for the Innovation Economy (CCIE)

What is the significance of cell and gene therapy in the field of modern medicine, and how does it differ from conventional drug treatments?  What are the potential economic benefits and opportunities associated with developing a strong cell and gene therapy manufacturing industry in Canada? How does the Canadian government’s focus on rebuilding vaccine-making capacity during the COVID-19 pandemic potentially impact the development of the cell and gene therapy industry?

Read the research for the full analysis.

Require an accessible version of this research?

Upon request, The Conference Board of Canada offers accessible versions of research. Please contact us to request your accessible version.

Learn more about our accessibility policies.

Reviews

Be the first to review “Out of the Lab, into the Patient: Canada’s Commercial Opportunity in Cell and Gene Therapy Manufacturing”

There are no reviews yet.